Lasts longer, causes more damage

Covid-19 pneumonia: not your typical garden-variety pneumonia

Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung within hours. In the modern intensive care unit, these bacteria or viruses are usually controlled either by antibiotics or by the body’s immune system within the first few days of the illness.

Photo
This CT scan of a 55-year-old male's lungs shows typical appearance of Covid pneumonia with bilateral and extensive ground glass opacities with right lower lobe consolidation.

But in a study published in Nature, investigators at Northwestern Medicine show Covid-19 pneumonia is different. Instead of rapidly infecting large regions of the lung, the virus causing Covid-19 sets up shop in multiple small areas of the lung. It then hijacks the lungs' own immune cells and uses them to spread across the lung over a period of many days or even weeks, like multiple wildfires spreading across a forest. As the infection slowly moves across the lung, it leaves damage in its wake and continuously fuels the fever, low blood pressure and damage to the kidneys, brain, heart and other organs in patients with Covid-19.

The severe complications of Covid-19 compared with other pneumonias might be related to the long course of disease rather than more severe disease, the study authors said. This is the first study in which scientists analyzed immune cells from the lungs of Covid-19 pneumonia patients in a systematic manner and compared them to cells from patients with pneumonia from other viruses or bacteria.

Recommended article

Photo

The role of chest CT in diagnosis and treatment

UPDATE: Covid-19 and lung infections imaging

RSNA 2020: International experts showcased new studies on chest CT’s role in Covid-19 diagnosis and treatment. A staggering volume of work and has been produced on the pandemic this year, with an average 367 Covid-19 journal articles published per week, according to Michael Chung, Assistant professor of radiology at Icahn School of Medicine at Mount Sinai, NYC.

As a result of the detailed analysis, researchers identified critical targets to treat severe SARS-CoV-2 pneumonia and lessen its damage. The targets are the immune cells: macrophages and T cells. The study suggests macrophages – cells typically charged with protecting the lung – can be infected by SARS-CoV-2 and can contribute to spreading the infection through the lung. Northwestern Medicine will test an experimental drug to treat these targets in Covid-19 pneumonia patients in a clinical trial early in 2021. The drug to be tested quiets the inflammatory response of these immune cells, thus enabling initiation of the repair process in the injured lung. “Our goal is to make Covid-19 mild instead of severe, making it comparable to a bad cold,” said study co-senior author Dr. Scott Budinger, chief of pulmonary and critical care medicine at Northwestern University Feinberg School of Medicine and Northwestern Medicine. “This effort truly represents a ‘moonshot’ in Covid-19 research,” said study co-senior author Dr. Richard Wunderink, professor of pulmonary and critical care medicine at Feinberg and medical director of Northwestern Medicine’s ICU. 

Covid-19, like influenza, is unlikely to ever go away, even if much of the population is vaccinated, said senior co-author Dr. Ben Singer, assistant professor of pulmonary and critical care medicine at Feinberg and a Northwestern Medicine physician. “Already, researchers at Northwestern and elsewhere are anticipating mechanisms by which this RNA virus, which mutates quickly, will evade current vaccines,” Singer said. “This study will help us develop treatments to reduce the severity of Covid-19 in those who develop it.”

Recommended article

Photo

Messenger RNA vaccines explained

Busting 8 common myths about Covid-19 vaccines

Even those who understand the scientific process, trust medical experts and know how important vaccines are for fighting infectious diseases might still have some questions or concerns about the new Covid-19 vaccines. Here, Thaddeus Stappenbeck, MD, PhD, helps set the record straight on 8 common questions, concerns and myths that have emerged about Covid-19 vaccines.

The study also revealed why the mortality among patients on a ventilator for Covid-19 was lower than patients on a ventilator due to regular pneumonia. An intense conflagration in the lungs (regular pneumonia) has a higher risk of death. Those with Covid-19 pneumonia are sick for a long time, but the inflammation in their lungs is not as severe as regular pneumonia. “If patients with Covid-19 are carefully managed and the health care system isn’t overwhelmed, you can get them through it,” Budinger said. “These patients are very sick. It takes a really long time for them to get better. But If you have enough beds and health care providers, you can keep the mortality to 20%. When health systems are overwhelmed mortality rates double up to 40%.”

For the study, scientists performed a high-resolution analysis of the lung fluid of 86 Covid-19 patients on a ventilator and compared it with lung fluid from 256 patients on a ventilator who had other types of pneumonia. Because of the safety concerns, only a handful of groups around the world performed analysis of the immune response in the lungs of patients with Covid-19. As a result, important information about what was killing patients with severe Covid-19 was missing.

Recommended article

Photo

Dangerous immune response

New insight on severe virus attacks on the lungs

In some cases, immune cells in the lungs can contribute to worsening a virus attack. In a new study, researchers at Karolinska Institutet describe how different kinds of immune cells, called macrophages, develop in the lungs and which of them may be behind severe lung diseases. The study, which was published in Immunity, may contribute to future treatments for Covid-19, among other diseases.

The current study is unique because Wunderink and colleagues have been studying pneumonia for years before the pandemic. As a result, when the Covid-19 pandemic hit, they were prepared to collect fluid from the lungs of these patients in a safe and systematic manner and compare it with fluid collected from other ICU patients with pneumonia collected before the pandemic. This research infrastructure allowed them to show that pneumonia in patients with Covid-19 is different from other pneumonia, and more importantly, how it is different.  

Scientists took cells from patients’ lung fluid and looked at the RNA and the proteins those cells express, enabling them to identify how these immune cells drive inflammation. ”This level of resolution could never be achieved without directly sampling lung fluid,” said study co-senior author Dr. Alexander Misharin, an assistant professor of pulmonary and critical care medicine at Feinberg and a Northwestern Medicine physician. The complex nature of the study, in which samples from patients were analyzed with the most sophisticated technologies available in Northwestern’s state-of-the art research labs, required the concerted effort of more than 100 researchers. 


Source: Northwestern Medicine

13.01.2021

Read all latest stories

Related articles

Photo

Xenios consoles as lifesavers

ECMO: crucial in the battle against COVID-19

As the coronavirus spreads and infections with COVID-19 further increase throughout Europe, ECMO therapy turns out to be a necessary option for patients with severe courses. Xenios AG, a subsidiary…

Photo

Dangerous immune response

New insight on severe virus attacks on the lungs

In some cases, immune cells in the lungs can contribute to worsening a virus attack. In a new study, researchers at Karolinska Institutet describe how different kinds of immune cells, called…

Photo

Coronavirus imaging

Covid-19: Is CT more sensitive than PCR testing?

Covid-19 causes characteristic changes in lung tissue visible in CT scans and chest radiographs. The “ground-glass” opacities are sharply delineated areas, bilateral and mainly located in the…